

17<sup>th</sup> July, 2019

The Dy. General Manager (Listing Dept.)  
BSE Limited  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: USFDA classifies inspection at Dahej facility as OAI**

The Company has received a communication from the USFDA classifying the inspection conducted at its Dahej facility in March, 2019 as Official Action Initiated (OAI).

The Company already had submitted its initial response to USFDA and commitments given in response to Form 483 observations have been fulfilled. The Company is sending further updates over receiving of this OAI letter. The Company will be engaging with the regulator and is fully committed in resolving this issue at the earliest.


The Company does not believe that this inspection classification will have an impact of disruption of supplies or the revenues from operations of this facility.

This is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



 MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY